BOCA RATON, Fla., Sept. 4, 2014 (GLOBE NEWSWIRE) -- RxStrategies, Inc. is pleased to announce the appointment of Rhodie Smith to National Sales Manager. In this new role, Rhodie joins the RxStrategies' senior leadership team and is responsible for sales and delivery of customized 340B pharmacy administration and split billing solutions to the growing 340B marketplace.
"I am very pleased to welcome Rhodie to the RxStrategies' senior leadership team," said Fenton Markevich, Chief Executive Officer for RxStrategies. "We look forward to incorporating Rhodie's deep 340B market and product expertise and knowledge for the benefit of our existing and future clients. We believe Rhodie will be a strong addition to our market facing team, and that he will help RxS highlight an enhanced 340B admin and split billing solution to existing clients and the overall 340B market."
Rhodie joins RxStrategies with acknowledged industry leadership and an extensive background in market facing roles to the 340B market. Rhodie is a graduate of University of Johannesburg and an alum of 340B University.
"RxStrategies has a strong reputation in the marketplace with both a unique and transparent processing solution, and a proprietary split billing solution for this complex market," said Smith. "I am excited to join a growing industry leader. I have spent my career using a consultative approach and I look forward to continuing that tradition by providing 340B guidance and insight to our current and future clients."
About RxStrategies, Inc.
Established in 2003 and headquartered in Boca Raton, Florida, RxStrategies, Inc. provides accountability, transparency and value-based solutions for the Federal 340B Drug Pricing Programs. As a full-service 340B Drug Pricing Program services organization, RxStrategies provides a diverse range of services to all "Qualified Entities" and the in-house and/or contract pharmacies, including 340B administration, split billing, orphan drug and audit services. RxStrategies' "real-time" comprehensive solutions are designed to meet the challenges of regulatory compliance, patient eligibility, pharmacy replenishment, program tracking and reporting of the Federal 340B Drug Pricing Program. To learn more, please visit www.340Bplus.com.
CONTACT: Cheryl Musial Media Relations Mopdog, Inc. email@example.com (678) 737-7325 Source:RxStrategies, Inc.